Chisato Imai-Boulter, Jean Li-Kim-Moy, Clayton Chiu, Sanjay Jayasinghe, Kristine Macartney
{"title":"澳大利亚在引入免疫接种前的呼吸道合胞病毒疾病负担和证据缺口:一项基于人群的回顾性研究,使用2016-2019年住院和2023年实验室监测数据。","authors":"Chisato Imai-Boulter, Jean Li-Kim-Moy, Clayton Chiu, Sanjay Jayasinghe, Kristine Macartney","doi":"10.5694/mja2.70289","DOIUrl":null,"url":null,"abstract":"<p><p>This study evaluated Australia's national respiratory syncytial virus (RSV) burden and highlighted key data gaps. Hospitalisations (2016-2019) peaked in infants aged < 3 months (4014/100,000) and adults aged ≥ 65 years (122/100,000), nearly doubling over the period. Unspecified causes comprised ≈55% of bronchiolitis hospitalisations in children aged < 24 months. Laboratory notifications (2023) peaked at 6-11 months (7778/100,000). Real-time data integration addressing case-ascertainment and diagnostic testing frequency is essential for accurate burden estimates and future immunisation strategies.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 9","pages":"e70289"},"PeriodicalIF":6.8000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13585565/pdf/","citationCount":"0","resultStr":"{\"title\":\"Respiratory Syncytial Virus Disease Burden and Evidence Gaps in Australia Before Immunisation Introduction: A Retrospective Population-Based Study Using 2016-2019 Hospitalisation and 2023 Laboratory Surveillance Data.\",\"authors\":\"Chisato Imai-Boulter, Jean Li-Kim-Moy, Clayton Chiu, Sanjay Jayasinghe, Kristine Macartney\",\"doi\":\"10.5694/mja2.70289\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study evaluated Australia's national respiratory syncytial virus (RSV) burden and highlighted key data gaps. Hospitalisations (2016-2019) peaked in infants aged < 3 months (4014/100,000) and adults aged ≥ 65 years (122/100,000), nearly doubling over the period. Unspecified causes comprised ≈55% of bronchiolitis hospitalisations in children aged < 24 months. Laboratory notifications (2023) peaked at 6-11 months (7778/100,000). Real-time data integration addressing case-ascertainment and diagnostic testing frequency is essential for accurate burden estimates and future immunisation strategies.</p>\",\"PeriodicalId\":18214,\"journal\":{\"name\":\"Medical Journal of Australia\",\"volume\":\"224 9\",\"pages\":\"e70289\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2026-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13585565/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Journal of Australia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5694/mja2.70289\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of Australia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5694/mja2.70289","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Respiratory Syncytial Virus Disease Burden and Evidence Gaps in Australia Before Immunisation Introduction: A Retrospective Population-Based Study Using 2016-2019 Hospitalisation and 2023 Laboratory Surveillance Data.
This study evaluated Australia's national respiratory syncytial virus (RSV) burden and highlighted key data gaps. Hospitalisations (2016-2019) peaked in infants aged < 3 months (4014/100,000) and adults aged ≥ 65 years (122/100,000), nearly doubling over the period. Unspecified causes comprised ≈55% of bronchiolitis hospitalisations in children aged < 24 months. Laboratory notifications (2023) peaked at 6-11 months (7778/100,000). Real-time data integration addressing case-ascertainment and diagnostic testing frequency is essential for accurate burden estimates and future immunisation strategies.
期刊介绍:
The Medical Journal of Australia (MJA) stands as Australia's foremost general medical journal, leading the dissemination of high-quality research and commentary to shape health policy and influence medical practices within the country. Under the leadership of Professor Virginia Barbour, the expert editorial team at MJA is dedicated to providing authors with a constructive and collaborative peer-review and publication process. Established in 1914, the MJA has evolved into a modern journal that upholds its founding values, maintaining a commitment to supporting the medical profession by delivering high-quality and pertinent information essential to medical practice.